FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, announced today its response to the recent U.S. Food and Drug Administration (FDA) Safety Communication.
The FDA's March 19, 2024, notice involved an ongoing assessment of certain plastic syringes. BD's president of Medication Delivery Solutions, Eric Borin, confirmed the company's increased manufacturing efforts to meet the rising syringe demand in the United States.
Borin stated that BD has augmented syringe production at its Nebraska and Connecticut facilities following the initial FDA safety communication in November. He emphasized BD's commitment to product safety and quality, noting that the latest FDA communication does not pertain to BD syringes. Borin also highlighted the company's historical role in healthcare, including the production of 2 billion additional syringes and needles to support the global COVID-19 pandemic response.
BD's efforts are part of their long-standing mission to enhance medical discovery, diagnostics, and care delivery. The company, which employs over 70,000 people, has been a key player in the health sector for more than 125 years. BD's global presence and partnerships aim to tackle some of the most pressing health challenges worldwide.
The company's dedication to quality and safety is further detailed on their website, where additional information about BD's practices and customer support can be found. This move by BD is expected to help ensure the continuity of patient care in the face of increased demand for medical supplies.
The information for this article is based on a press release statement from BD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.